The Role of Extracellular Vesicles in the Diagnosis and Prognosis of Inflammatory Diseases

John Milly^*
*Correspondence: John Milly, Department of Biomedical Diagnostics, Stanford University,, USA, Email:

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, with tumors exhibiting complex and heterogeneous genetic profiles that contribute to their progression, metastasis, and resistance to therapy. Early and accurate detection of cancer is critical for improving treatment outcomes, as it allows for timely intervention and better patient prognostication. Traditional diagnostic methods, including imaging and biopsy, often fall short in providing precise information about tumor heterogeneity and molecular characteristics. As a result, there has been an increasing focus on identifying tumor-specific biomarkers that can facilitate early diagnosis, predict treatment responses, and monitor disease progression. Functional genomics approaches, which include techniques such as RNA Sequencing (RNA-Seq), CRISPR-based screens, and gene expression profiling, are emerging as powerful tools in the search for such biomarkers. These methodologies enable a deeper understanding of the genetic alterations and cellular mechanisms that drive tumor development and metastasis, thus providing valuable insights into cancer biology and potential therapeutic targets. By linking molecular changes to functional outcomes, functional genomics can help identify tumor-specific biomarkers that are not only predictive of disease but also relevant for clinical decision-making [1].

Functional genomics offers a comprehensive approach to identifying cancer biomarkers by studying the functional effects of genetic variations within the context of the tumor microenvironment. Unlike traditional genomic approaches, which focus primarily on the sequence and structure of DNA, functional genomics aims to understand how genetic changes influence cellular function, behavior, and interactions within the tumor. For example, techniques like CRISPR-Cas9 screens and RNA interference (RNAi) can be used to perturb specific genes and observe the resulting phenotypic changes, which can help pinpoint genes crucial for tumor survival and metastasis. By targeting specific mutations or genes that drive tumorigenesis, functional genomics provides a means of identifying potential biomarkers that are specific to individual tumors or subtypes of cancer, thereby enabling personalized medicine. Furthermore, multi-omics approaches, integrating genomic, transcriptomic, and proteomic data, have enhanced the discovery of tumor-specific biomarkers that are not only informative for diagnosis but also for treatment planning, enabling the development of more tailored and effective therapies [2].

Description

RNA sequencing (RNA-Seq) is one of the most widely used functional genomics tools for identifying tumor-specific biomarkers. By measuring gene expression levels across the entire transcriptome, RNA-Seq allows researchers to detect both known and novel genes that are dysregulated in cancer cells. In particular, this technique can identify differentially expressed genes (DEGs) between tumor and normal tissues, providing insights into the molecular mechanisms of tumorigenesis. For instance, in lung cancer, RNA-Seq has identified several genes associated with poor prognosis, including those involved in cell cycle regulation, apoptosis, and DNA repair. Furthermore, RNA-Seq can be used to explore the expression of long non-coding RNAs (lncRNAs), which have recently gained attention for their role in regulating gene expression and tumor progression. These lncRNAs, which are often tumor-specific, can serve as novel biomarkers for early detection, metastasis prediction, and therapeutic targeting. Additionally, RNA-Seq can help uncover alternative splicing events that may lead to the generation of tumor-specific isoforms of proteins, further expanding the scope for biomarker discovery. As RNA-Seq technologies continue to improve in terms of sensitivity and throughput, their ability to identify cancer-specific biomarkers with high accuracy becomes increasingly valuable in clinical settings [3].

 

In addition to RNA-Seq, CRISPR-based functional screens have emerged as powerful tools in the discovery of tumor-specific biomarkers. The CRISPR-Cas9 genome-editing system allows for precise modification of the genome, enabling researchers to knock out or activate specific genes and observe the resulting cellular phenotypes. This approach has been widely adopted in cancer research to identify genes that are essential for tumor cell survival, proliferation, and metastasis. For example, CRISPR screens in breast cancer have identified oncogenes and tumor suppressor genes that drive tumorigenesis, many of which were previously unknown or underexplored. By systematically perturbing genes across the entire genome, CRISPR screens can reveal novel tumor-specific biomarkers that are critical for cancer progression. These biomarkers, in turn, can be used to stratify patients based on their tumor’s genetic profile, allowing for more personalized treatment strategies. Moreover, CRISPR-based screens can be combined with drug screening platforms to identify potential therapeutic targets, making this a powerful tool not only for biomarker discovery but also for the development of new cancer therapies [4].

 

In addition to CRISPR and RNA-Seq, epigenomic profiling techniques, such as DNA methylation and histone modification analysis, are playing an increasingly important role in identifying tumor-specific biomarkers. Epigenetic alterations, which can influence gene expression without changing the underlying DNA sequence, are frequently observed in cancer cells and contribute to tumorigenesis, metastasis, and therapy resistance. DNA methylation patterns, for example, are often distinct in cancer cells compared to normal cells, with certain genes being hyper methylated or hypo methylated in tumor tissues. DNA methylation biomarkers are particularly useful because they are stable and can be detected in body fluids such as blood, making them valuable for non-invasive diagnostics. Similarly, changes in histone modifications, such as acetylation and methylation, can provide additional layers of information regarding tumor-specific alterations in gene regulation. By combining epigenomic with genomic data, researchers can identify a comprehensive set of biomarkers that reflect both the genetic and epigenetic changes driving tumor development. This integrated approach has the potential to uncover multi-faceted tumor-specific biomarkers that can be used for early detection, prognosis prediction, and monitoring of therapeutic responses [5].

Conclusion

In conclusion, functional genomics approaches are significantly advancing the field of cancer biomarker discovery. Techniques such as RNA sequencing, CRISPR-based screens, and epigenomic profiling offer powerful tools for identifying tumor-specific biomarkers that can improve cancer diagnosis, prognosis, and treatment. These approaches allow researchers to gain a deeper understanding of the molecular alterations driving tumorigenesis and to pinpoint genes and regulatory networks that are essential for tumor survival and progression. By integrating multi-omics data and focusing on functional outcomes, these technologies enable the discovery of more precise, tumor-specific biomarkers that can guide clinical decision-making and enable personalized medicine. Furthermore, the identification of novel biomarkers not only aids in early cancer detection but also in predicting responses to therapy and monitoring disease recurrence. As functional genomics technologies continue to evolve, they will play an increasingly critical role in cancer diagnostics, offering new avenues for earlier intervention, more effective treatments, and better outcomes for cancer patients.

References

1.  Grivennikov, Sergei I., Florian R. Greten and Michael Karin. "Immunity, inflammation and cancer." Cell 140 (2010): 883-899.

Google Scholar, Crossref, Indexed at

2. Valihrach, Lukas, Peter Androvic and Mikael Kubista. "Circulating miRNA analysis for cancer diagnostics and therapy." Mol Asp Med 72 (2020): 100825.

Google Scholar, Crossref, Indexed at